Dr. Dolly Jacob: Solubility & Bioavailability
Dr. Dolly Jacob, Director of Integrated Development Services at Quotient Sciences featured in Drug Development & Delivery looking at the challenges of solubility & bioavailability.
Dr. Vanessa Zann: Pharmaceutical Technology Contribution
Dr. Vanessa Zann, Senior Drug Development Consultant at Quotient Sciences featured in Pharmaceutical Technology looking at the important role of early-phase biopharmaceutics.
Quotient Sciences Contributes to Clinical Pharmacology in Drug Development article, "A Phase 1 Study of Savolitinib"
Quotient Sciences experts contribute to a recent article in the American College of Clinical Pharmacology® Clinical Pharmacology in Drug Development journal that highlights the results of an ADME study of AstraZeneca's savolitinib.
Quotient Sciences Expands Formulation Development Capabilities at Nottingham, UK
An expansion of our early-phase formulation development capabilities for oral dosage forms at our Nottingham, UK, facility builds upon our existing formulation capabilities.
Ensysce Biosciences' PF614-MPAR Enters Final Stage of Phase 1 Study
Ensysce Biosciences' PF614-MPAR, could be the industry's first overdose protection pain product, now entering a final Phase 1 study with Quotient Sciences.
HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801
HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company focusing on novel multifunctional therapeutics for metabolic and digestive diseases, and Quotient Sciences, a drug development and manufacturing accelerator, have signed an agreement to support HighTide’s HTD1801 program.